Intracameral antibiotics: questions for the United States based on prospective studies.
Recent prospective studies from Europe suggest the use of intracameral antibiotics for prophylaxis of endophthalmitis, although the studies did not make a comparison with the most common United States prophylaxis techniques. Thus, the European studies as well as the present literature were reviewed in an attempt to place the European studies in perspective with regard to the present U.S. protocol and the available literature. There is no worldwide-established approach to prophylaxis of endophthalmitis. In the absence of a strong evidence-based approach most surgeons use surrogate studies to support their techniques and mold their opinions based on their interpretation of the literature and when they believe organisms causing endophthalmitis enter the eye. The review showed that preoperative topical antibiotics limit the number of bacteria on the ocular surface at surgery and postoperative topical antibiotics are most appropriate to address postoperative inoculation until the wound is sealed (with no tapering). Whereas intracameral antibiotic injection may be an appropriate route of administration to address inoculation occurring at the time of surgery, more research on safety and effectiveness is needed before we expose the millions of eyes having cataract surgery each year. A multipronged approach to limit endophthalmitis risk is also needed, with antibiotics as only part of the strategy.
Liesegang
Thomas J
TJ
Mayo Clinic, Jacksonville, Florida 32224, USA. tliesegang@mayo.edu
D000867:Anterior Chamber / Q000187:drug effects*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects; D019072:Antibiotic Prophylaxis; D009877:Endophthalmitis / Q000517:prevention & control*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D019654:Lens Implantation, Intraocular; D009883:Ophthalmic Solutions / Q000008:administration & dosage* / Q000009:adverse effects; D018918:Phacoemulsification; D011310:Preservatives, Pharmaceutical / Q000008:administration & dosage / Q000009:adverse effects; D011446:Prospective Studies; D012307:Risk Factors; D014481:United States
D000900:Anti-Bacterial Agents; D009883:Ophthalmic Solutions; D011310:Preservatives, Pharmaceutical